Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03989362 · ClinicalTrials.gov registry record · Phase 2
Vopratelimab and a CTLA-4 Inhibitor in PD-1/PD-L1 Inhibitor Experienced Subjects With NSCLC or Urothelial Cancer
A Phase 2 study, sponsored by Jounce Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 61
- Enrollment target
NCT03989362: Completed Phase 2 study, sponsored by Jounce Therapeutics.
NCT03989362 is a Phase 2 study that has completed, run by Jounce Therapeutics. The registered enrollment target is 61 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03989362, a Phase 2 study, has completed, sponsored by Jounce Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 61 participants
- Enrollment target
Study Summary
JTX-2011-201 is a Phase 2, open label clinical study of vopratelimab (JTX-2011) and ipilimumab in adult subjects with non-small cell lung cancer (NSCLC) or urothelial cancer to evaluate safety and efficacy.
Interventions
- DRUG Ipilimumab
- DRUG Vopratelimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2019-06-06 |
| Est. Completion | 2022-03-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03989362
The ClinicalTrials.gov registry entry for NCT03989362 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jounce Therapeutics, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ipilimumab is the first listed.
NCT03989362 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03989362 about?
NCT03989362 is a clinical study titled "Vopratelimab and a CTLA-4 Inhibitor in PD-1/PD-L1 Inhibitor Experienced Subjects With NSCLC or Urothelial Cancer". JTX-2011-201 is a Phase 2, open label clinical study of vopratelimab (JTX-2011) and ipilimumab in adult subjects with non-small cell lung cancer (NSCLC) or urothelial cancer to evaluate safety and efficacy.
What is the current status of trial NCT03989362?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 61 participants. The study started on 2019-06-06. Estimated completion is 2022-03-15.
What interventions are being tested in trial NCT03989362?
The interventions under investigation include: Ipilimumab (DRUG), Vopratelimab (DRUG).
Who is sponsoring clinical trial NCT03989362?
This trial is sponsored by Jounce Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.